ADC Therapeutics SA (ADCT) dropped 30.54% to $3.19 after the company released updated results from its LOTIS-7 Phase 1b trial, evaluating ZYNLONTA in combination with a bispecific antibody for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
ADCT said the new data reinforce the potential for a best-in-class regimen, showing encouraging antitumor activity and a manageable safety profile in a heavily pretreated, high-risk population. The company highlighted that the combination demonstrated meaningful responses even in patients who had progressed on multiple prior lines of therapy.
On Friday, ADCT opened at $4.50, reached a high of $4.57, and a low of $3.03, compared to a previous close of $4.60 on the NYSE. Trading volume surged well above average, reflecting unusually heavy activity following the announcement. The stock's 52-week range is $1.31 - $6.04.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.